GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (STU:2I9) » Definitions » EV-to-FCF

Karolinska Development AB (STU:2I9) EV-to-FCF : -16.02 (As of May. 20, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Karolinska Development AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Karolinska Development AB's Enterprise Value is €31.24 Mil. Karolinska Development AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.95 Mil. Therefore, Karolinska Development AB's EV-to-FCF for today is -16.02.

The historical rank and industry rank for Karolinska Development AB's EV-to-FCF or its related term are showing as below:

STU:2I9' s EV-to-FCF Range Over the Past 10 Years
Min: -116.42   Med: -9.99   Max: 352.79
Current: -16.25

During the past 13 years, the highest EV-to-FCF of Karolinska Development AB was 352.79. The lowest was -116.42. And the median was -9.99.

STU:2I9's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.59 vs STU:2I9: -16.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-20), Karolinska Development AB's stock price is €0.1238. Karolinska Development AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.010. Therefore, Karolinska Development AB's PE Ratio for today is 12.38.


Karolinska Development AB EV-to-FCF Historical Data

The historical data trend for Karolinska Development AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB EV-to-FCF Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.50 -8.29 57.85 -8.05 -14.61

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.19 -11.22 -11.36 -14.61 -15.29

Competitive Comparison of Karolinska Development AB's EV-to-FCF

For the Biotechnology subindustry, Karolinska Development AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's EV-to-FCF falls into.



Karolinska Development AB EV-to-FCF Calculation

Karolinska Development AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=31.238/-1.95
=-16.02

Karolinska Development AB's current Enterprise Value is €31.24 Mil.
Karolinska Development AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB  (STU:2I9) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Karolinska Development AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.1238/0.010
=12.38

Karolinska Development AB's share price for today is €0.1238.
Karolinska Development AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.010.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Karolinska Development AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (STU:2I9) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Karolinska Development AB (STU:2I9) Headlines

No Headlines